MENU
FMS
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

Fresenius Medical Care AG (FMS) Earnings Date & Reports

Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025... Show more

A.I. Advisor
published Earnings

FMS is expected to report earnings to fall 29.65% to 65 cents per share on February 23

Fresenius Medical Care AG FMS Stock Earnings Reports
Q4'26
Est.
$0.65
Q2'26
Beat
by $0.31
Q1'26
Beat
by $0.48
Q4'25
Beat
by $1.11
Q3'25
Beat
by $0.53
The last earnings report on August 03 showed earnings per share of 92 cents, beating the estimate of 62 cents. With 887.10K shares outstanding, the current market capitalization sits at 12.45B.
A.I.Advisor
Nov 03, 2026

Fresenius Medical Care (FMS) Third Quarter 2026 Earnings Recap: A China Charge Clouds a Steady Quarter

Key Takeaways

  • Fresenius Medical Care reported third quarter 2026 revenue of €4.94 billion, up 1% year over year, while organic growth was essentially flat at 0.1%.
  • Net income attributable to shareholders fell 42% to €160 million, pressured by roughly €108 million in one-time costs tied to the company's revised China strategy.
  • Adjusted basic earnings per share (EPS, or profit allocated to each outstanding share) rose slightly to €1.11, compared with €1.10 in the prior-year quarter.
  • Management narrowed its full-year 2026 operating income outlook to flat-to-negative mid-single-digit growth, citing expected fourth-quarter headwinds.
  • The FME25+ cost-transformation program delivered €74 million in sustainable savings during the quarter, keeping the company on track for its €250 million full-year target.
  • For additional context on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
  • Discover automated trading strategies powered by artificial intelligence through Trending AI Robots.

Earnings Context and Why It Matters

Fresenius Medical Care is the world's largest provider of kidney dialysis products and services, making its quarterly results a key barometer for the broader renal-care industry. This report arrives in the middle of a multi-year transformation, as the company consolidates clinics, refines its manufacturing footprint, and rolls out its 5008X CAREsystem dialysis machines. The quarter also marked a shift in reimbursement dynamics, with the Transitional Drug Add-on Payment Adjustment (TDAPA, a temporary U.S. Medicare payment add-on for certain dialysis drugs) moving from a tailwind to a headwind as phosphate-binder payments phase down. Investors were watching whether underlying operational improvements could offset those pressures and a costly strategic reset in China.

Reported Results

Group revenue increased 1% to €4,937 million, compared with €4,885 million a year earlier, though it declined 1% at constant currency and edged up just 0.1% organically. Reported operating income fell 19% to €384 million, with a margin of 7.8%, while operating income excluding special items declined 5% to €545 million, producing an 11.0% margin.

Reported net income attributable to shareholders dropped 42% to €160 million, and basic EPS fell 35% to €0.61 from €0.94. The decline was driven largely by special items, which totaled a net negative €161 million, including roughly €108 million in one-time costs related to a China strategy refinement that involved impairment, scrappage, and termination expenses. Adjusted net income was €291 million, down from €322 million, while adjusted basic EPS inched up to €1.11 from €1.10, supported by the company's share buyback program.

On guidance, Fresenius Medical Care kept its revenue expectation of broadly flat growth for fiscal 2026 but narrowed its operating income outlook to between flat and a negative mid-single-digit percentage, down from a prior range that allowed for modest growth.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-focused names like Fresenius Medical Care, the AI Screener can help identify comparable opportunities across the healthcare sector and beyond.

Market Reaction and Investor Sentiment

Shares edged lower following the release, with the stock trading modestly down on both European and U.S. exchanges. The initial reaction reflected a mixed read: stable revenue and slightly higher adjusted EPS were encouraging, but the narrowed operating income guidance and the scale of China-related special items weighed on sentiment. Investors also noted that adjusted operating income declined 6% at constant currency, underscoring that inflation and TDAPA reimbursement headwinds are still pressuring margins even as cost savings progress. The company's active buyback program, which had repurchased 3.4% of share capital by the end of September, provided a partial offset to the cautious tone.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching how the company manages the fourth-quarter TDAPA headwind, which management expects to intensify as the phosphate-binder payment period winds down. The pace of the 5008X CAREsystem rollout is another focal point; by the end of September, the company had converted 348 clinics, or about 14% of its U.S. network, and installed roughly 9,000 machines, keeping it on track to convert 20% of its install base by year-end.

Inflationary pressures, particularly in the Care Enablement segment, remain a key risk to margins, as do lingering effects from weaker patient referrals earlier in the year. On the positive side, the FME25+ program continues to generate meaningful savings, and the company's capital allocation framework, including its second €1 billion share buyback, signals confidence in long-term cash generation.

Investors should also monitor any further updates on the China business restructuring and the broader trajectory of the Value-Based Care segment, which is working through a change in the risk structure of one contract. The company's ability to hold margins near current levels while absorbing these headwinds will be central to the narrative into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of renal and dialysis products

Industry HospitalNursingManagement

Industry
Medical Or Nursing Services
Address
Else-Kroner-Strasse 1
Phone
+49 61726090
Employees
109698
Web
https://www.freseniusmedicalcare.com